Literature DB >> 20661584

The effect of laser unit on photodynamic therapy spot size.

Siamak Ansari-Shahrezaei1, Susanne Binder, Michael Stur.   

Abstract

BACKGROUND: To determine the effect of the laser unit on photodynamic therapy (PDT) spot size.
METHODS: A calibrated Gullstrand-type model eye was used for this study. The axial length of the model eye was set to different values ranging from 22.2 to 27.0 mm, and the actual spot size from the laser console was recorded for treating a spot of 4 mm in the center of the artificial fundus using two different laser units (Coherent Opal laser; Coherent Inc, Santa Clara, California, USA and Zeiss Visulas laser; Carl Zeiss Meditec Inc, Dublin, California, USA) and two indirect contact laser lenses (Volk PDT laser lens and Volk Area Centralis lens; Volk Optical Inc, Mentor, Ohio, USA).
RESULTS: From myopia to hyperopia, the total deviation from the intended spot size was -22.5% to -7.5% (Opal laser and PDT laser lens), and -17.5% to +2.5% (Visulas laser and PDT laser lens), -12.5% to +7.5% (Opal laser and Area Centralis lens), and -7.5% to +10% (Visulas laser and Area Centralis lens).
CONCLUSIONS: The used laser unit has a significant effect on PDT spot size in this model. These findings may be important for optimizing PDT of choroidal neovascular lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661584     DOI: 10.1007/s00417-010-1460-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  19 in total

1.  The effect of axial length on photodynamic therapy.

Authors:  Siamak Ansari-Shahrezaei; Erdem Ergun; Michael Stur
Journal:  Am J Ophthalmol       Date:  2006-04       Impact factor: 5.258

2.  Magnification-corrected photodynamic therapy.

Authors:  Siamak Ansari-Shahrezaei; Erdem Ergun; Robert Chong; Adnan Tufail; Andreas Wedrich; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.117

3.  Refractive error and smoking habits in exudative age-related macular degeneration in a hospital-based setting.

Authors:  Y Tao; J B Jonas
Journal:  Eye (Lond)       Date:  2009-07-10       Impact factor: 3.775

4.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

5.  [A model of Gullstrand's "normal eye"].

Authors:  B Rassow
Journal:  Ophthalmologica       Date:  1972       Impact factor: 3.250

6.  Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment.

Authors:  D Husain; M Kramer; A G Kenny; N Michaud; T J Flotte; E S Gragoudas; J W Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-09       Impact factor: 4.799

7.  Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.

Authors:  Laurence Postelmans; Brigitte Pasteels; Pascale Coquelet; Hind El Ouardighi; Claire Verougstraete; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2004-11       Impact factor: 5.258

8.  Refraction, axial length and age-related maculopathy.

Authors:  Solveig Otteren Ulvik; Johan H Seland; Tore Wentzel-Larsen
Journal:  Acta Ophthalmol Scand       Date:  2005-08

9.  Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.

Authors:  M Kramer; J W Miller; N Michaud; R S Moulton; T Hasan; T J Flotte; E S Gragoudas
Journal:  Ophthalmology       Date:  1996-03       Impact factor: 12.079

10.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.

Authors:  Andrew N Antoszyk; Lisa Tuomi; Carol Y Chung; Angele Singh
Journal:  Am J Ophthalmol       Date:  2008-03-05       Impact factor: 5.258

View more
  3 in total

1.  Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.

Authors:  E Smretschnig; S Hagen; C Glittenberg; R Ristl; I Krebs; S Binder; S Ansari-Shahrezaei
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

2.  The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.

Authors:  Stefan Hagen; Siamak Ansari-Shahrezaei; Eva Smretschnig; Carl Glittenberg; Ilse Krebs; Alexandra Graf; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-29       Impact factor: 3.117

3.  Factors affecting laser power in retinal Navilas laser treatment.

Authors:  Alexandra E Hoeh; Stefanie Pollithy; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-27       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.